US EditionLiquidia receives $50 million in funding related to taking drug to market - Business North Carolina
Summary by Business North Carolina
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Liquidia receives $50 million in funding related to taking drug to market - Business North Carolina
Liquidia Technologies received $50 million in additional funding related to its first commercial sale of its drug Yutrepia on June 2. The drug received FDA approval in May for the treatment of pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease. Liquidia has now received $175 million of the potential $200 million in funding under an agreement with Healthcare Royalty Partners. Liquidia will…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
